IMMUNE AND MORPHOLOGICAL PHENOTYPES OF KIDNEY ALLOGRAFT INJURY
https://doi.org/10.24884/1561-6274-2017-21-6-9-19
Abstract
Long-term outcome of kidney transplantation is limited by the development of allograft rejection due to activation and realization of Tand B-cell immune response as well as the effects of other types of immune reactions mediated by various mechanisms. This article is dedicated to nowadays point of view upon the different immune and morphological phenotypes of kidney transplant injury. Main focus is made on the pathways of microvascular inflammation in the case of donor-specific antibodies absence as the unique self-sustained phenotype of the kidney allograft injury.
About the Authors
V. A. Dobronravov
Research Institute of Nephrology Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
Vladimir A. Dobronravov - MD, PhD, DSci, vice director.
197022, Lva Tostogo str. 17
M. S. Khrabrova
First Pavlov Saint-Petersburg State Medical University
Russian Federation
Russian Federation
Maria S. Khrabrova - MD, PhD, Department of Propedeutics of Internal Diseases Assistant prof.
197022, Saint-Petersburg, Str. Leo Tolstoy, 17 build 54, +78123380165
References
1. Бикбов БТ, Томилина НА. Заместительная терапия больных с хронической почечной недостаточностью методами перитонеального диализа и трансплантации почки в Российской Федерации в 1998-2011 г. (Отчет по данным Российского регистра заместительной почечной терапии. Часть вторая). Нефрология и диализ 2014; 16(2): 192-227 [BikbovBT, TomilinaNA. ZamestitelnayaterapiyabolnichskhronicheskoypochechnoynedostatochnostiumetodamiperitonealnogodializaitransplantaciipochkivRossiyskoyFederaciiv 1998-2011 g. (OtchetpodannimRossiyskogoregistrazamestitelnoypochechnoyterapii. Chast vtoraya). Nefrologiya i dializ 2014; 16 (2): 192-227]
2. Jain P, Cockwell P, Little J et al. Survival and transplantation in end-stage renal disease: a prospective study of a multiethnic population. Nephrol Dial Transplant 2009; 24(12): 3840-3846. doi: 10.1093/ndt/gfp455
3. Tonelli M, Wiebe N, Knoll G et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11(10): 2093-2109. doi: 10.1111/j.1600-6143.2011.03686.x
4. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying Specific Causes of Kidney Allograft Loss. Am J Transplant 2009; 9(3): 527-535. doi: 10.1111/j.1600-6143.2008.02519.x
5. Davis CL, Hricik DE. Transplant: immunology and treatment of rejection. Am J Kidney Dis 2004; 43(6): 1116-1137
6. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012; 93(1): 1-10. doi: 10.1097/TP.0b013e31823cab44
7. Robinson J, Halliwell JD, Hayhurst JD et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015; 43: D423-431. doi: 10.1093/nar/gku1161
8. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3(6): 708-714. doi: 10.1034/j.1600-6143.2003.00072.x
9. Solez K, Colvin RB, Racusen LC et al. Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7(3): 518-526. doi: 10.1111/j.1600-6143.2006.01688.x
10. Haas M, Sis B, Racusen LC et al. Banff 2013 Meeting Report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14(2): 272-283. doi: 10.1111/ajt.12590
11. Loupy A, Haas M, Solez K et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant 2017; 17 (1): 28-41. doi: 10.1111/ajt.14107
12. Nabokow A, Dobronravov VA, Khrabrova MS et al. Long-term kidney allograft survival in patients with transplant glomerulitis. Transplantation 2015; 99(2): 331-339. doi: 10.1097/TP.0000000000000606
13. Morris PJ, Knechtle SJ. Kidney Transplantation: principles and practice, 6th ed. Saunders Elsevier, United States of America, 2008; 9-23
14. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going? Transplant Rev (Orlando) 2017; 31(1): 10-17. doi: 10.1016/j.trre.2016.10.006
15. Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 2010; 10(5): 1126-1134. doi: 10.1111/j.1600-6143.2010.03053.x
16. Huang Y, Farkash E. Protocol Biopsies: Utility and Limitations. Adv Chronic Kidney Dis 2016; 23(5): 326-331. doi: 10.1053/j.ackd.2016.09.002.
17. Wu K, Budde K, Rudolph B et al. Designation of T-cellmediated rejection type Ib and IIa reflects the type of rejection rather than the severity in the Banff classification. Exp Clin Transplant 2014; 12(5): 415-423. doi: 10.6002/ect.2014.0050
18. Wu K, Budde K, Lu H et al. The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation 2014; 97(11): 1146-1154. doi: 10.1097/01.TP.0000441094.32217.05
19. Lamarche C, Cote JM, Senecal L et al. Efficacy of Acute Cellular Rejection Treatment According to Banff Score in KidneyTransplant Recipients: A Systematic Review. Transplant Direct 2016; 15(2): e115. doi: 10.1097/TXD.0000000000000626
20. Halloran PF, Chang J, Famulski K et al. Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol 2015; 26(7): 1711-1720. doi: 10.1681/ASN.2014060588
21. Lefaucheur C, Loupy A, Vernerey D et al. Antibody mediated vascular rejection of kidney allografts: a populationbased study. Lancet 2013; 9863: 313-319. doi: 10.1016/S0140-6736(12)61265-3
22. Knechtle SJ, Heisey DM, Pirsch JD et al. Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. Surgery 1996; 120 (4): 719-724
23. Mengel M, Reeve J, Bunnag S et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9(8): 1859-1867. doi: 10.1111/j.1600-6143.2009.02727.x
24. Mannon RB, Matas AJ, Grande J et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10(9): 2066-2073. doi: 10.1111/j.1600-6143.2010.03240.x
25. Sis B, Bagnasco SM, Cornell LD et al. Isolated endarteritis and kidney transplant survival: a multicenter collaborative study. J Am Soc Nephrol 2015; 26(5): 1216-1227. doi: 10.1681/ASN.2014020157
26. Haas M, Kraus ES, Samaniego-Picota M et al. Acute renal allograft rejection with intimal arteritis: histologic predictors of responseto therapy and graft survival. Kidney Int 2002; 61(4): 1516-1526. doi: 10.1046/j.1523-1755.2002.00254.x
27. Rodriguez Cubillo B, Perez Flores I, Calvo N et al. AntibodyMediated Acute Vascular Rejection of Kidney Allografts: FifteenYear Follow-up. Transplant Proc 2016; 48(9): 2917-2919. doi: 10.1016/j.transproceed.2016.09.015.
28. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18(4): 10461056. doi: 10.1681/ASN.2007010073
29. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation 2013; 95(9): 1073-1083. doi: 10.1097/TP.0b013e31827e6b45
30. Wang S, Zhang C, Wang J et al. Endothelial Cells in Antibody Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implication. J Immunol Res 2017; 2017: 8746303. doi: 10.1155/2017/8746303
31. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8(11): 670-678. doi: 10.1038/nrneph.2012.212
32. Mengel M, Sis B, Haas M et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12(3): 563-570. doi: 10.1111/j.1600-6143.2011.03926.x
33. Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients. Transplant Rev (Orlando) 2017; 31(1): 47-54. doi: 10.1016/j.trre.2016.10.004
34. Butler CL, Valenzuela NM, Thomas KA, Reed EF. Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. J Immunol Res 2017; 2017: 7903471. doi: 10.1155/2017/7903471
35. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9(11): 2520-2531. doi: 10.1111/j.1600-6143.2009.02799.x
36. De Kort H, Willicombe MP, Brookes MP et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13(2): 485-492. doi: 10.1111/j.1600-6143.2012.04325.x
37. Loupy A, Hill GS, Suberbielle C et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11(1): 56-65. doi: 10.1111/j.1600-6143.2010.03364.x
38. Dragun D, Hoff U, Park JK et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000; 58(5): 2166-77. doi: 10.1111/j.15231755.2000.00390.x
39. Zhang Q, Reed EF. The importance of non-HLA antibodies in transplantation. Nature reviews Nephrology 2016; 12(8): 484-495. doi: 10.1038/nrneph.2016.88
40. Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. TransplImmunol 2010; 22(3-4): 105-109. doi: 10.1016/j.trim.2009.12.005
41. Храброва МС, Добронравов ВА, Набоков АВ и др. Микроваскулярное воспаление как прогностический фактор при трансплантации почки. Нефрология 2015; 19(5): 34-4 [KhrabrovaMS, DobronravovVA, NabokovAVidr. Mikrovaskulyarnoevospaleniekakprognosticheskiyfactorpritransplantaciipochki. Nefrologiya 2015; 19 (5): 34-41]
42. Petra H, Eva H, Irena B et al. Molecular profiling of acute and chronic rejections of renal allografts. Clin Dev Immunol 2013; 509259. doi: 10.1155/2013/509259
43. Willicombe M, Roufosse C, Brookes P et al. Acute cellular rejection: impact of donor-specific antibodies and C4d. Transplantation 2014; 97(4): 433-439. doi: 10.1097/01.TP.0000437431.97108.8f
44. Matignon M, Muthukumar T, Seshan SV et al. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation 2012; 94(6): 603-611. doi: 10.1097/TP.0b013e31825def05
45. Bagnasco SM, Kraus ES. Intimal arteritis in renal allografts: new takes on an old lesion. Curr Opin Organ Transplant 2015; 20 (3): 343-347. doi: 10.1097/MOT.0000000000000186
46. Loupy A, Vernerey D, Tinel C et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26(7): 1721-1731. doi: 10.1681/ASN.2014040399
47. Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12(5): 1157-1167. doi: 10.1111/j.1600-6143.2012.04013.x
48. Randhawa P. T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance. Curr Opin Organ Transplant 2015; 20(3): 325-332. doi: 10.1097/MOT.0000000000000189
49. Batal I, Lunz JG, Aggarwal N et al. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant 2010; 10(11): 2442-2452. doi: 0.1111/j.1600-6143.2010.03261.x
50. Buob D, Grimbert P, Glowacki F et al. Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients. Transpl Int 2012; 25(6): 663-670. doi: 10.1111/j.1432-2277.2012.01473.x
51. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7(10): 803-815. DOI: 10.1038/nri2171
52. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82(5): 521-533
53. Devi S, Li A, Westhorpe CL et al. Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus. Nat Med 2013; 19(1): 107-112. doi: 10.1038/nm.3024
54. Finsterbusch M, Hall P, Li A et al. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus. Proc Natl Acad Sci USA 2016; 113 (35): E5172-5181. doi: 10.1073/pnas.1606253113
55. Hayde N, Bao Y, Pullman J et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013; 8(12): 2141-2148. doi: 10.2215/CJN.04240413
56. Homs S, Mansour H, Desvaux D et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant 2009; 9(5): 1230-1236. doi: 10.1111/j.1600-6143.2009.02596.x
57. Magil AB. Infiltrating cell types in transplant glomerulitis: relationship to peritubular capillary C4d deposition. Am J Kidney Dis 2005; 45(6): 1084-1089. doi: -
58. Gupta A, Broin PÓ, Bao Y et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int 2016; 89(1): 217-225. doi: 10.1038/ki.2015.276
59. Fu H, Kishore M, Gittens B et al. Self-recognition of the endothelium enables regulatory T cell trafficking and definesthe kinetics of immune regulation. Nat Commun 2014; 14(5): 3436. doi: 10.1038/ncomms4436
60. Tinckam K, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68(4): 1866-1874. doi: 10.1111/j.1523-1755.2005.00606.x
61. Giaretta F, Bussolino S, Beltramo S et al. Different regulatory and cytotoxic CD4+ T lymphocyte profiles in renal transplants with antibody-mediated chronic rejection or long-term good graft function. Transpl Immunol 2013; 28(1): 48-56. doi: 10.1016/j. trim.2012.11.003
62. Dummer CD, Carpio VN, Gonçalves LF et al. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 2012; 26(1): 1-10. doi: 10.1016/j.trim.2011.08.009
63. Rose ML. Role of anti-vimentin antibodies in allograft rejection. Hum Immunol 2013; 74(11): 1459-1462. doi: 10.1016/j.humimm.2013.06.006
64. Nielsen CT. Circulating microparticles in systemic Lupus Erythematosus. Dan Med J 2012; 59(11): B4548
65. Dye JR, Ullal AJ, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol 2013; 78(2): 140-148. doi: 10.1111/sji.12068.
66. Grau V, Zeuschner P, Immenschuh S. Immune ComplexType Deposits in the Fischer-344 to Lewis Rat Model of Renal Transplantation and a Subset of Human Transplant Glomerulopathy. Transplantation 2016; 100(5): 1004-1014. doi: 10.1097/TP.0000000000001068
67. Djamali A, Kaufman DB, Ellis TM et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014; 14 (2): 255-271. doi: 10.1111/ajt.12589. Epub 2014 Jan 8
68. Добронравов ВА, Храброва МС, Мухаметдинова АО, Сиповский ВГ. Частотавыявленияипрогнозантительноопосредованногоотторженияприаллотрансплантациипочки. Нефрология 2016; 20(6): 82-89 [DobronravovVA, KhrabrovaMS, MukhametdinovaAO, SipovskiyVG. Chastotavyiavleniyaiprognosantitelno-oposredovannogoottorjeniapriallotransplantaciipochki. Nefrologiya 2016; 20(6): 82-89]
69. Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7(9): 2124-2132. doi: 10.1111/j.1600-6143.2007.01895.x
70. Husain S, Sis B. Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 2013; 62(2): 352-363. doi: 10.1053/j.ajkd.2012.10.026
71. Lesage J, Noël R, Lapointe I et al. Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation 2015; 99(1): 69-76. doi: 10.1097/TP.0000000000000310
72. Fotheringham J, Angel CA, McKane W. Transplant glomerulopathy: morphology, associations and mechanism. Nephron Clin Pract 2009; 113(1): 1-7. doi: 0.1159/000228069
73. Remport A, Ivanyi, Z, Mathe B et al. Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection. Nephrol Dial Transplant 2014; 30(11): 1825-1833. doi: 10.1093/ndt/gfu371
74. Orandi BJ, Chow EH, Hsu A et al. Quantifying renal allograft loss following early antibody-mediated rejection. AmJTransplant 2015; 15(2): 489-498. doi: 10.1111/ajt.12982
75. Столяревич ЕС, Ильинский ИМ, Тырин ВВ, Томилина НА. Хроническая трансплантационная нефропатия: клиникоморфологические сопоставления. Нефрология и диализ 2001; 3 (1): 32 [StolyarevichES, IliinskiyIM, TyirinVV, Tomilina NA. Khronicheskayatransplantacionnayanefropatiya: kliniko morfologicheskiye sopostavleniya. Nefrologiya i dializ 2001; 3(1): 32]
Review
For citations:
Dobronravov V.A., Khrabrova M.S. IMMUNE AND MORPHOLOGICAL PHENOTYPES OF KIDNEY ALLOGRAFT INJURY. Nephrology (Saint-Petersburg). 2017;21(6):9-19. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-6-9-19
Views:
1232
Email this article 